These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 28800947)
21. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411 [TBL] [Abstract][Full Text] [Related]
22. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients]. Broner J; Arnaud E Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884 [TBL] [Abstract][Full Text] [Related]
23. [Giant-cell arteritis pathogenesis]. Samson M; Bonnotte B Presse Med; 2012 Oct; 41(10):937-47. PubMed ID: 22902103 [TBL] [Abstract][Full Text] [Related]
25. New Therapeutic Approaches to Large-Vessel Vasculitis. Kaymakci MS; Warrington KJ; Kermani TA Annu Rev Med; 2024 Jan; 75():427-442. PubMed ID: 37683286 [TBL] [Abstract][Full Text] [Related]
26. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy. Yoshifuji H Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262 [TBL] [Abstract][Full Text] [Related]
27. Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. Nordborg E; Nordborg C Rheumatology (Oxford); 2003 Mar; 42(3):413-21. PubMed ID: 12626790 [TBL] [Abstract][Full Text] [Related]
28. [How to manage giant cell arteritis]. Allali D; Blondon M; Roux-Lombard P; Spoerl D Rev Med Suisse; 2020 Jan; 16(676-7):12-15. PubMed ID: 31961075 [TBL] [Abstract][Full Text] [Related]
32. Pathogenesis of giant cell arteritis: new insight into the implication of CD161+ T cells. Samson M; Audia S; Martin L; Janikashvili N; Bonnotte B Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S65-73. PubMed ID: 23663684 [TBL] [Abstract][Full Text] [Related]
33. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis. Jogimahanti AV; Kini AT; Irwin LE; Lee AG J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267 [TBL] [Abstract][Full Text] [Related]
34. Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice. Paroli M; Caccavale R; Accapezzato D Cells; 2024 Jan; 13(3):. PubMed ID: 38334659 [TBL] [Abstract][Full Text] [Related]
35. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases. Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427 [TBL] [Abstract][Full Text] [Related]
36. Tocilizumab for the treatment of giant cell arteritis. Schirmer M; Muratore F; Salvarani C Expert Rev Clin Immunol; 2018 May; 14(5):339-349. PubMed ID: 29676602 [TBL] [Abstract][Full Text] [Related]
37. Current management of giant cell arteritis and its complications. Galli E; Muratore F; Warrington KJ Curr Opin Rheumatol; 2024 Sep; 36(5):344-350. PubMed ID: 38920090 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic approach to giant cell arteritis. Masson C Joint Bone Spine; 2012 May; 79(3):219-27. PubMed ID: 22119350 [TBL] [Abstract][Full Text] [Related]
39. Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index. Berti A; Cornec D; Medina Inojosa JR; Matteson EL; Murad MH Semin Arthritis Rheum; 2018 Aug; 48(1):77-82. PubMed ID: 29496228 [TBL] [Abstract][Full Text] [Related]